Business Context and Reporting Period
This Form 8-K Current Report was filed by AntriaBio, Inc. on July 17, 2017. The filing reports the completion of an additional close of an ongoing planned private placement transaction (the "PIPE Financing") with investors in the Republic of Korea. The transaction was conducted pursuant to Section 4(a)(2) of the Securities Act of 1933 and Rule 506 of Regulation D.
Key Financial Metrics
- Gross Proceeds: $4.5 million (excluding transaction costs, fees, and expenses).
- Shares Issued: 4,500,000 shares of Common Stock.
- Purchase Price: $1.00 per share.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational or balance sheet metrics.
Material Changes
The primary material change reported is the capital raise via the issuance of 4.5 million shares to Korean investors. This represents an additional close of a financing plan previously initiated (referenced by a Purchase Agreement filed on March 6, 2017). The company granted registration rights to the investors, agreeing to file a registration statement within 30 days of the final close to allow for the resale of the shares.
Guidance, Outlook, and Risks
- Registration Rights: The Company agreed to file a registration statement within 30 days following the final close of the PIPE Financing and maintain its effectiveness until shares are available for resale under Rule 144.
- Regulatory Status: The securities were sold unregistered under Section 4(a)(2) and Rule 506. They may not be offered or sold in the United States absent registration or an applicable exemption.
- Disclosure Status: The press release associated with this transaction is furnished under Regulation FD and is not deemed "filed" for purposes of the Securities Exchange Act of 1934.
- Outlook: The filing text does not provide specific forward-looking guidance or management commentary regarding future operations beyond the financing completion.
Investor Verification Checklist
- Verify the total aggregate amount raised in the entire PIPE Financing, as this filing only covers an "additional close."
- Confirm the filing date and effectiveness of the Registration Statement promised to investors within 30 days of the final close.
- Review the full text of the Purchase Agreement (Exhibit 10.1) for specific covenants, liquidation preferences, or other terms not summarized in this report.
- Check subsequent filings to determine if the final close of the PIPE Financing has occurred and if the registration statement was filed as agreed.